不同剂量地西他滨联合CAG方案治疗骨髓增生异常综合征的疗效及安全性

Efficacy and Safety of Different Doses Dicitabine combined CAG Regimen in the Treatment of Myelodysplastic Syndrome

目的比较不同剂量地西他滨联合CAG方案治疗骨髓增生异常综合征(MDS)的疗效及安全性。方法选取2018年1月至2021年12月南通大学附属医院及分院收治的86例中高危MDS患者作为研究对象,采用随机数字表法分为观察组与对照组,各43例。对照组予以标准剂量地西他滨联合CAG方案治疗,观察组采用小剂量地西他滨联合CAG方案治疗,比较两组的治疗效果、血液学毒性、不良反应。结果观察组治疗有效率为79.07%,与对照组的83.72%比较,差异无统计学意义(P>0.05);化疗第14天时观察组白细胞计数(WBC)、中性粒细胞(NE)、血红蛋白(Hb)、血小板计数(PLT)高于对照组,差异有统计学意义(P<0.05);观察组不良反应发生率为65.17%,低于对照组的88.37%(P<0.05)。结论小剂量地西他滨联合CAG方案治疗MDS与标准剂量地西他滨疗法的疗效相似,但血液学毒性及不良反应更小。

Objective To compare the efficacy and safety of different doses of decitabine combined with CAG in the treatment of myelodysplastic syndrome(MDS).Methods A total of 86 patients with moderate and high-risk MDS admitted to the Affiliated Hospital of Nantong University from January 2018 to December 2021 were selected as the study objects,and were divided into observation group and control group by random number table method,with 43 cases in each group.The control group was treated with standard dose decitabine combined with CAG,and the observation group was treated with low-dose decitabine combined with CAG.The therapeutic effect,hematological toxicity and adverse reactions of the two groups were compared.Results The effective rate of the observation group was 79.07%,compared with 83.72%of the control group,there was no significant difference(P>0.05).On the 14th day of chemotherapy,the white blood cell count(WBC),neutrophil(NE),hemoglobin(Hb)and platelet count(PLT)in observation group were higher than those in control group,and the differences were statistically significant(P<0.05).The incidence of adverse reactions in observation group was 65.17%,which was lower than 88.37%in control group(P<0.05).Conclusion The efficacy of low-dose decitabine combined with CAG in the treatment of MDS is similar to that of standard dose decitabine therapy,but the hematological toxicity and adverse reactions are less.